AOD-9604: Benefits, Dosage & FDA Status
Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
FDA Status
Not FDA-approved — Category 1 (compounding allowed)
Typical Dose
250–500 mcg daily (subcutaneous)
Evidence Grade
C+Preclinical evidence + anecdotal clinical use
Half-Life
~30 minutes
Routes of Administration
subcutaneous, oral (research only)
First Synthesized
1990s
Clinics Indexed
134 providers have offered AOD-9604 in our tracked directory.
Mechanism of Action
C-terminal fragment of hGH (177–191) hypothesized to stimulate lipolysis without IGF-1 elevation; also explored for cartilage repair.
Key Reported Benefits
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C+ indicates preclinical evidence + anecdotal clinical use.
Reported Side Effects
- •Generally well-tolerated
- •Mild injection-site reactions
Contraindications
- ⚠Pregnancy
Commonly Stacked With
Tesamorelin
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
CJC-1295 (no DAC)
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Regulatory & Safety Context
FDA status: Not FDA-approved — Category 1 (compounding allowed)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on AOD-9604. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Semaglutide
A+A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
Tirzepatide
A+A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
Tesamorelin
AAn FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
Liraglutide
A+The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
Retatrutide
ATriple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
Cagrilintide
AA once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.